▶ 調査レポート

ライム病治療の世界市場2021年-2031年:治療別(医薬品、ダニ除去)、バクテリア別、投与経路別、用途別、流通チャンネル別

• 英文タイトル:Lyme Disease Treatment Market (Treatment Type: Medication and Tick Removal; Type of Bacteria: Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, Borrelia garinii, and Others; Route of Administration: Oral, Injectable, and Topical; Application: Humans and Animals; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Transparency Market Researchが調査・発行した産業分析レポートです。ライム病治療の世界市場2021年-2031年:治療別(医薬品、ダニ除去)、バクテリア別、投与経路別、用途別、流通チャンネル別 / Lyme Disease Treatment Market (Treatment Type: Medication and Tick Removal; Type of Bacteria: Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, Borrelia garinii, and Others; Route of Administration: Oral, Injectable, and Topical; Application: Humans and Animals; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031 / MRC2109A040資料のイメージです。• レポートコード:MRC2109A040
• 出版社/出版日:Transparency Market Research / 2021年6月11日
• レポート形態:英文、PDF、266ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Site Licence¥1,301,660 (USD8,795)▷ お問い合わせ
  Enterprisewide¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の本調査レポートは、ライム病治療の世界市場について調査し、序論、仮定、調査手法、エグゼクティブサマリー、市場概要、主要インサイト、治療別(医薬品、ダニ除去)分析、投与経路別分析、バクテリア別分析、用途別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などを掲載しております。
・序論
・仮定
・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・ライム病治療の世界市場規模:治療別(医薬品、ダニ除去)
・ライム病治療の世界市場規模:投与経路別
・ライム病治療の世界市場規模:バクテリア別
・ライム病治療の世界市場規模:用途別
・ライム病治療の世界市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況

Lyme Disease Treatment Market – Scope of Report

TMR’s report on the global Lyme disease treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market over the forecast period from 2021 to 2031. The report provides the overall revenue of the global Lyme disease treatment market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global Lyme disease treatment market for the forecast period of 2021–2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global Lyme disease treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomena in the global Lyme disease treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the Lyme disease treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the Lyme disease treatment market.

The report also delves into the competitive landscape of the global Lyme disease treatment market. Key players operating in the global Lyme disease treatment market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the Lyme disease treatment market profiled in this report.

Key Questions Answered in Lyme Disease Treatment Market Report

How does the development of Lyme disease treatment provide scope of growth in the global Lyme disease treatment market?
How alliances and partnerships among players are widening the scope of new line of therapies for Lyme disease treatment?
What are the revenue share projections of key segments under various criteria in the Lyme disease treatment market during the forecast period?
Which segment is likely to register highest revenue until the end of the forecast period in 2031?
How is the evolving healthcare system in developing countries in Asia Pacific making an impact on the overall Lyme disease treatment market?
Lyme Disease Treatment Market – Research Objectives and Research Approach

The comprehensive report on the global Lyme disease treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in the purview of line of procedure for Lyme disease treatment.

For reading comprehensibility, the report is compiled in a chapter-wise layout, with each section further divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Lyme disease treatment market in terms of treatment type, type of bacteria, route of administration, application, distribution channel, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Lyme disease treatment market.

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lyme Disease Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lyme Disease Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.2. Key Industry Events (mergers and acquisitions, new product development, technological advancements, etc.)
5.3. Lyme Disease Treatment Overview
5.4. Severity of Diseases (Lyme Arthritis, Carditis and Neurological Symptoms)
5.5. Epidemiology of Lyme Disease Region/Country
5.6. Tick Geography Analysis by Respective Countries
6. Global Lyme Disease Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Medication
6.3.1.1. Antibiotics
6.3.1.1.1. Cephalosporin
6.3.1.1.2. Tetracycline
6.3.1.1.3. Macrolides
6.3.1.1.4. Others
6.3.1.2. NSAID
6.3.1.3. Others
6.3.2. Tick Removal
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Lyme Disease Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Injectable
7.3.3. Topical
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Lyme Disease Treatment Market Analysis and Forecast, by Type of Bacteria
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Type of Bacteria, 2017–2031
8.3.1. Borrelia burgdorferi
8.3.2. Borrelia mayonii
8.3.3. Borrelia afzelii
8.3.4. Borrelia garinii
8.3.5. Others
8.4. Market Attractiveness Analysis, by Type of Bacteria
9. Global Lyme Disease Treatment Market Analysis and Forecast, by Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Humans
9.3.2. Animals
9.4. Market Attractiveness Analysis, by Application
10. Global Lyme Disease Treatment Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Lyme Disease Treatment Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Country/Region
12. North America Lyme Disease Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Medication
12.2.1.1. Antibiotics
12.2.1.1.1. Cephalosporin
12.2.1.1.2. Tetracycline
12.2.1.1.3. Macrolides
12.2.1.1.4. Others
12.2.1.2. NSAID
12.2.1.3. Others
12.2.2. Tick Removal
12.3. Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Oral
12.3.2. Injectable
12.3.3. Topical
12.4. Market Value Forecast, by Type of Bacteria, 2017–2031
12.4.1. Borrelia burgdorferi
12.4.2. Borrelia mayonii
12.4.3. Borrelia afzelii
12.4.4. Borrelia garinii
12.4.5. Others
12.5. Market Value Forecast, by Application, 2017–2031
12.5.1. Humans
12.5.2. Animals
12.6. Market Value Forecast, by Distribution Channel, 2017–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Treatment Type
12.8.2. By Route of Administration
12.8.3. By Type of Bacteria
12.8.4. By Application
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Lyme Disease Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Medication
13.2.1.1. Antibiotics
13.2.1.1.1. Cephalosporin
13.2.1.1.2. Tetracycline
13.2.1.1.3. Macrolides
13.2.1.1.4. Others
13.2.1.2. NSAID
13.2.1.3. Others
13.2.2. Tick Removal
13.3. Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Oral
13.3.2. Injectable
13.3.3. Topical
13.4. Market Value Forecast, by Type of Bacteria, 2017–2031
13.4.1. Borrelia burgdorferi
13.4.2. Borrelia mayonii
13.4.3. Borrelia afzelii
13.4.4. Borrelia garinii
13.4.5. Others
13.5. Market Value Forecast, by Application, 2017–2031
13.5.1. Humans
13.5.2. Animals
13.6. Market Value Forecast, by Distribution Channel, 2017–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Treatment Type
13.8.2. By Route of Administration
13.8.3. By Type of Bacteria
13.8.4. By Application
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Lyme Disease Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2017–2031
14.2.1. Medication
14.2.1.1. Antibiotics
14.2.1.1.1. Cephalosporin
14.2.1.1.2. Tetracycline
14.2.1.1.3. Macrolides
14.2.1.1.4. Others
14.2.1.2. NSAID
14.2.1.3. Others
14.2.2. Tick Removal
14.3. Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Oral
14.3.2. Injectable
14.3.3. Topical
14.4. Market Value Forecast, by Type of Bacteria, 2017–2031
14.4.1. Borrelia burgdorferi
14.4.2. Borrelia mayonii
14.4.3. Borrelia afzelii
14.4.4. Borrelia garinii
14.4.5. Others
14.5. Market Value Forecast, by Application, 2017–2031
14.5.1. Humans
14.5.2. Animals
14.6. Market Value Forecast, by Distribution Channel, 2017–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Treatment Type
14.8.2. By Route of Administration
14.8.3. By Type of Bacteria
14.8.4. By Application
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Lyme Disease Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Type, 2017–2031
15.2.1. Medication
15.2.1.1. Antibiotics
15.2.1.1.1. Cephalosporin
15.2.1.1.2. Tetracycline
15.2.1.1.3. Macrolides
15.2.1.1.4. Others
15.2.1.2. NSAID
15.2.1.3. Others
15.2.2. Tick Removal
15.3. Market Value Forecast, by Route of Administration, 2017–2031
15.3.1. Oral
15.3.2. Injectable
15.3.3. Topical
15.4. Market Value Forecast, by Type of Bacteria, 2017–2031
15.4.1. Borrelia burgdorferi
15.4.2. Borrelia mayonii
15.4.3. Borrelia afzelii
15.4.4. Borrelia garinii
15.4.5. Others
15.5. Market Value Forecast, by Application, 2017–2031
15.5.1. Humans
15.5.2. Animals
15.6. Market Value Forecast, by Distribution Channel, 2017–2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Treatment Type
15.8.2. By Route of Administration
15.8.3. By Type of Bacteria
15.8.4. By Application
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Lyme Disease Treatment Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Treatment Type, 2017–2031
16.2.1. Medication
16.2.1.1. Antibiotics
16.2.1.1.1. Cephalosporin
16.2.1.1.2. Tetracycline
16.2.1.1.3. Macrolides
16.2.1.1.4. Others
16.2.1.2. NSAID
16.2.1.3. Others
16.2.2. Tick Removal
16.3. Market Value Forecast, by Route of Administration, 2017–2031
16.3.1. Oral
16.3.2. Injectable
16.3.3. Topical
16.4. Market Value Forecast, by Type of Bacteria, 2017–2031
16.4.1. Borrelia burgdorferi
16.4.2. Borrelia mayonii
16.4.3. Borrelia afzelii
16.4.4. Borrelia garinii
16.4.5. Others
16.5. Market Value Forecast, by Application, 2017–2031
16.5.1. Humans
16.5.2. Animals
16.6. Market Value Forecast, by Distribution Channel, 2017–2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Treatment Type
16.8.2. By Route of Administration
16.8.3. By Type of Bacteria
16.8.4. By Application
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (by Tier and Size of companies)
17.2. Market Share Analysis/Ranking, by Company, 2020
17.3. Company Profiles
17.3.1. GlaxoSmithKline plc
17.3.1.1. Company Description
17.3.1.2. Business Overview
17.3.1.3. Strategic Overview
17.3.1.4. SWOT Analysis
17.3.2. Pfizer, Inc.
17.3.2.1. Company Description
17.3.2.2. Business Overview
17.3.2.3. Strategic Overview
17.3.2.4. SWOT Analysis
17.3.3. Novartis AG
17.3.3.1. Company Description
17.3.3.2. Business Overview
17.3.3.3. Strategic Overview
17.3.3.4. SWOT Analysis
17.3.4. F. Hoffmann-La Roche Ltd.
17.3.4.1. Company Description
17.3.4.2. Business Overview
17.3.4.3. Strategic Overview
17.3.4.4. SWOT Analysis
17.3.5. Almirall, LLC
17.3.5.1. Company Description
17.3.5.2. Business Overview
17.3.5.3. Strategic Overview
17.3.5.4. SWOT Analysis
17.3.6. Mayne Pharma
17.3.6.1. Company Description
17.3.6.2. Business Overview
17.3.6.3. Strategic Overview
17.3.6.4. SWOT Analysis
17.3.7. Boehringer Ingelheim International GmbH
17.3.7.1. Company Description
17.3.7.2. Business Overview
17.3.7.3. Strategic Overview
17.3.7.4. SWOT Analysis
17.3.8. Galderma Laboratories, L.P.
17.3.8.1. Company Description
17.3.8.2. Business Overview
17.3.8.3. Strategic Overview
17.3.8.4. SWOT Analysis
17.3.9. Lupin Pharmaceuticals, Inc.
17.3.9.1. Company Description
17.3.9.2. Business Overview
17.3.9.3. Strategic Overview
17.3.9.4. SWOT Analysis
17.3.10. Chartwell Pharmaceuticals
17.3.10.1. Company Description
17.3.10.2. Business Overview
17.3.10.3. Strategic Overview
17.3.10.4. SWOT Analysis
17.3.11. Sun Pharmaceutical Industries Ltd.
17.3.11.1. Company Description
17.3.11.2. Business Overview
17.3.11.3. Strategic Overview
17.3.11.4. SWOT Analysis
17.3.12. Perrigo Company plc
17.3.12.1. Company Description
17.3.12.2. Business Overview
17.3.12.3. Strategic Overview
17.3.12.4. SWOT Analysis
17.3.13. Orion Corporation
17.3.13.1. Company Description
17.3.13.2. Business Overview
17.3.13.3. Strategic Overview
17.3.13.4. SWOT Analysis
17.3.14. Amneal Pharmaceuticals LLC
17.3.14.1. Company Description
17.3.14.2. Business Overview
17.3.14.3. Strategic Overview
17.3.14.4. SWOT Analysis

List of Tables

Table 01: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

Table 02: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031

Table 03: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 04: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 05: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031

Table 06: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 07: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 08: Global Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Region/Country, 2017–2031

Table 09: North America Lyme Disease Treatment Market Revenue (US$ Mn) Forecast, by Country, 2017–2031

Table 10: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

Table 11: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031

Table 12: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 13: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 14: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031

Table 15: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 16: North America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

Table 19: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031

Table 20: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 21: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 22: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031

Table 23: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Europe Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 25: Asia Pacific Lyme Disease Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2015–2031

Table 26: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

Table 27: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031

Table 28: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 29: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 30: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031

Table 31: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 32: Asia Pacific Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 33: Latin America Lyme Disease Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 34: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

Table 35: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031

Table 36: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 37: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 38: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031

Table 39: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 40: Latin America Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 41: Middle East & Africa Lyme Disease Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 42: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2031

Table 43: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Medication, 2017–2031

Table 44: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Antibiotics, 2017–2031

Table 45: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 46: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Type of Bacteria, 2017–2031

Table 47: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 48: Middle East & Africa Lyme Disease Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031